Orientation of Classroom Teachers of Language-Handicapped Pupils

Abstract not availabl

Facilitators and barriers in the physical therapy of patients with musculoskeletal impairments during the COVID-19 pandemic

The study determined the facilitators and barriers in the physical therapy of patients with musculoskeletal (MSK) impairments during the COVID-19 pandemic as to the processes of client management model: examination, evaluation, diagnosis, prognosis, intervention, and outcome. It also determined the insights of physical therapists (PTs) as to the enrichment of facilitators and addressing of the barriers. A qualitative-descriptive approach was utilized in order to generate an in-depth understanding of the experiences of the target population through one-on-one interviews. The researchers utilized semi-structured interview questions that were pilot tested to two (2) participants and validated by the three (3) experts. The eight (8) participants in the study were the PTs who practiced in selected cities in Cavite that had the highest incidence rate of musculoskeletal conditions for the years 2020 and 2021, based on the list obtained from the Department of Health Research Center for Health and Development CALABARZON IV-A. They were also those who delivered in-person rehabilitation in various practice settings such as: home health, hospitals, and rehabilitation clinics. After each interview, the researchers performed three (3) levels of transcription and the data extracted were subjected to a thematic analysis. Three (3) main themes have emerged after analyzing the data that was gathered, namely: (1) Pandemic Boosters for Musculoskeletal Physical Therapy, (2) Pandemic Currents that deter Musculoskeletal Physical Therapy, and (3) The Way to Go Forward. In each component of the client management model, it was mostly the government-imposed protocols, interdisciplinary collaboration, administrative policies, and skills of physical therapists as to MSK assessment and treatment that either supported or restricted the physical therapy of patients. Results from the study encompassing what can enrich the facilitators and address the barriers may serve as a recommendation to continue delivering rehabilitative care despite the limitations brought by the pandemic

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.Y

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

BACKGROUND: KW-2478 is a novel non-ansamycin Hsp90 inhibitor with modest single-agent activity in relapsed/refractory myeloma but which shows synergistic antimyeloma activity with bortezomib (BTZ) in preclinical studies. This study determined the safety, preliminary clinical activity, and pharmacokinetics of KW-2478, an Hsp90 inhibitor, in combination with BTZ in patients with relapsed/refractory multiple myeloma (MM). METHODS: Phase I dose escalation determined the recommended phase II dose (RP2D) of KW-2478 plus BTZ, which was then used during phase II. RESULTS: The maximum tolerated dose was not reached during phase I and the RP2D was KW-2478 175 mg m−2 plus BTZ 1.3 mg m−2 on days 1, 4, 8, and 11 every 3 weeks. In the efficacy evaluable phase I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4–50.9%), clinical benefit rate 51.9% (40.4–63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months. In the phase I/II safety population (n=95), the most frequently observed treatment-related grade 3/4 adverse events were diarrhoea, fatigue, and neutropenia (each in 7.4% of patients), and nausea and thrombocytopenia (each in 5.3%). CONCLUSIONS: KW-2478 plus BTZ was well tolerated with no apparent overlapping toxicity in patients with relapsed/refractory MM. The antimyeloma activity of KW-2478 in combination with BTZ as scheduled in this trial appeared relatively modest; however, the good tolerability of the combination would support further exploration of alternate dosing schedules and combinations